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During sexual transmission of HIV, virus crosses
mucosal epithelium and eventually reaches lymphoid
tissue where it establishes a permanent infection.
Evidence has accumulated that infection of
Langerhans cells, which are resident dendritic cells in
pluristrati®ed epithelia, plays a crucial role in the
early events of HIV transmission. HIV infection of
Langerhans cells is regulated by surface expression of
CD4 and CCR5. Thus, topical microbicides that
interfere with HIV infection of Langerhans cells
represent an attractive strategy for blocking sexual
transmission of virus. Capture and uptake of HIV
virions is another major pathway by which HIV
interacts with dendritic cells. By contrast, this pro-
cess is mediated by a newly described C-type lectin,
DC-SIGN. It is well established that HIV-exposed
dendritic cells transmit virus ef®ciently to cocultured
T cells. Indeed, dendritic cell±T cell interaction,
critical in the generation of immune responses, is a
rich microenvironment for HIV replication both
in vitro and in vivo. Dendritic cells that have captured
virus via DC-SIGN, and not HIV-infected dendritic
cells, probably facilitate most infection of T cells in
chronically infected individuals. Therefore, blocking
DC-SIGN-mediated capture of HIV represents a
potential therapeutic antiviral strategy for HIV
disease. Lastly, dendritic cells have been targeted
both ex vivo and in vivo to initiate and enhance HIV-
speci®c immunity. Although these approaches are
promising for both therapeutic and prophylactic vac-
cines, much additional work is needed in order to
optimize dendritic-cell-based immunization strat-
egies. Key words: Langermans cells/cells/CCRS/DC-
SIGN/AIDS. J Invest Dermatol 119:365±369, 2002
O
ver the past two decades, the world has witnessed
the phenomenal spread of HIV and its consequence
of ending human lives. HIV infection has destroyed
not only the lives of individuals, but also entire
global regions. A 2001 report from UNAIDS/
WHO stated that HIV has killed over 20 million people worldwide
(Piot et al, 2001). The major mode of infection is heterosexual
intercourse. Small amounts of virus traverse mucosal surfaces to
reach replication-competent sites in lymphoid tissue. Now, it is
well established that Langerhans cells, resident myeloid dendritic
cells, play an important role at this early stage of infection. In this
review, we will summarize the evidence supporting the pivotal role
of Langerhans cells/dendritic cells in HIV disease and highlight
some of the new developments in this research ®eld that could have
important implications in both the prevention and treatment of
AIDS.
GENERAL FEATURES OF LANGERHANS CELLS/
DENDRITIC CELLS
Langerhans cell progenitors reside in the bone marrow (Katz et al,
1979). After circulation in blood, they home to epithelial surfaces,
where Langerhans cells remain in a resting ``immature'' state until
encountering antigen. Immature resident Langerhans cells/dendri-
tic cells have a highly active endocytic system that is carefully
coordinated in order for ef®cient antigen processing to occur
(Pierre and Mellman, 1998; Garrett et al, 2000; Turley et al, 2000).
Upon exposure to a variety of stimuli, including bacterial
lipopolysaccharide (Rescigno et al, 1999), tumor necrosis factor
family ligands, e.g., TNF-ab (Caux et al, 1992), CD40L (Caux et
al, 1994), FasL (Rescigno et al, 2000), bacterial DNA, or double
stranded RNA (Cella et al, 1997), Langerhans cells/dendritic cells
are activated and switch from an immature to a mature antigen
presenting state. This switch involves upregulation of a variety of
molecules known to be important in activating T cells (e.g., major
histocompatibility complex (MHC) class II, CD80, CD86). As
well, maturation is closely linked with the migration of Langerhans
cells from skin to secondary lymphoid organs, and this process is
regulated through chemokine receptors (e.g., CCR7) and multi-
drug resistance receptors. Within lymphoid organs, antigen-
activated Langerhans cells/dendritic cells interact with antigen-
speci®c T cells, initiating immune responses (Banchereau et al,
2000).
Several types of human dendritic cells have been identi®ed. At
least two subsets exist in human skin: epidermal Langerhans cells,
which express CD1a and the Birbeck-granule-associated protein
langerin (CD207), and dermal dendritic cells (Lenz et al, 1993;
Nestle et al, 1993; Banchereau et al, 2000). In human blood, at least
two major dendritic cell subsets can be distinguished, including
CD11c+ CD123± myeloid dendritic cells and CD11c± CD123+
plasmacytoid dendritic cells (Grouard et al, 1997). Like Langerhans
cells, blood myeloid dendritic cells are major initiators of adaptive
or acquired immune responses, whereas the blood plasmacytoid
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dendritic cells are involved in innate immune responses.
Speci®cally, the latter cells are the major source of interferon-a
produced during viral infections (Cella et al, 1999; Siegal et al,
1999).
INFECTION OF DENDRITIC CELLS BY HIV
Numerous investigators have shown that HIV infects Langerhans
cells and other types of myeloid dendritic cells both in vivo and
in vitro (Tschachler et al, 1987; Ringler et al, 1989; Zambruno et al,
1991; Stahl-Hennig et al, 1999; Hu et al, 2000). In addition, HIV
infection of blood plasmacytoid dendritic cells, the major producers
of type I interferons, has recently been described (Patterson et al,
2001).
Accumulating evidence for infection in dendritic cells, however,
has not always been easy to acquire. One reason for this is that
dendritic cells represent relatively rare populations of cells within
tissue (e.g., Langerhans cells represent 2%±3% of all epidermal
cells). A second reason stems from the fact that dendritic cells
represent a cell population that is capable of migrating rapidly from
epithelial tissue following contact with antigen. Thus, certain
investigators were unable to detect SIV+ Langerhans cells within
mucosal tissue 2±3 d following intravaginal or intraoral inoculation
of virus (Stahl-Hennig et al, 1999; Zhang et al, 1999). By contrast,
when vaginal tissue was examined only 18 h after intravaginal
exposure, SIV-infected intraepithelial Langerhans cells could easily
be found (Hu et al, 2000). Virus could also be recovered in lymph
nodes in a dendritic-cell-associated form at this early time point
(Hu et al, 2000). Lastly, HIV infection of dendritic cells both in vivo
and in vitro has been dif®cult to detect because viral replication in
dendritic cells occurs at much lower levels than CD4+ T cells, cells
most commonly studied by HIV researchers. In particular, most
studies have shown that HIV replication (i.e., productive infection)
in mature dendritic cell populations is blocked completely or occurs
only at very low levels (Cameron et al, 1992b; Granelli-Piperno et
al, 1998; Bakri et al, 2001).
Like infection in CD4+ T cells and other cell types, HIV
infection of dendritic cells requires CD4 and an HIV coreceptor
(Granelli-Piperno et al, 1996; Ayehunie et al, 1997; Blauvelt et al,
1997; Zaitseva et al, 1997; Kawamura et al, 2000). The chemokine
receptors CCR5 and CXCR4 are the major HIV coreceptors. HIV
types that utilize CCR5 as a coreceptor are termed R5 viruses
(previously termed macrophage-tropic or nonsyncytium-inducing
viruses), whereas types that utilize CXCR4 are termed X4 viruses
(previously termed T cell line tropic or syncytium-inducing
viruses). In general, immature dendritic cells tend to express higher
levels of CCR5 and little or no surface CXCR4, whereas mature
dendritic cells tend to express less CCR5 and higher levels of
CXCR4 (Sallusto et al, 1998; Kawamura et al, 2001).
It is critical to understand and consider dendritic cell maturation-
associated HIV coreceptor expression changes when performing
HIV infection experiments involving dendritic cells, as well as
when interpreting the signi®cance/relevance of these experiments
to the pathogenesis of HIV disease. For example, it is now known
that R5 viruses are the predominant types of viruses to be
transmitted from individual to individual, as well as the types of
viruses that are dominant in early stage HIV disease (Zhang et al,
1993; Zhu et al, 1993). Interestingly, individuals with a
homozygous mutation in the open reading frame of ccr5, in
whom no functional CCR5 protein can be detected, are relatively
protected from acquiring HIV despite (in some cases) numerous
exposures (Huang et al, 1996; Liu et al, 1996; Samson et al, 1996).
In addition, we strengthened the idea of a central role of CCR5 in
sexual transmission of HIV by ®rst reporting that immature
Langerhans cells express CCR5 but no surface CXCR4, suggesting
that Langerhans cells act as gatekeepers by allowing only R5
infection through mucosa (Zaitseva et al, 1997). More recently, we
and others have shown that resident epidermal Langerhans cells can
become easily infected ex vivo with R5 viruses, but not by X4
viruses (Reece et al, 1998; Kawamura et al, 2000). Currently, we are
involved in the design and testing of small molecule inhibitors that
bind CCR5 and prevent R5 HIV infection (Kawamura et al, 2000);
these compounds are synthetic analogs of the chemokine
RANTES, a natural ligand for CCR5. The ultimate goal of this
project is to develop a topical drug formulation, or microbicide,
that could prevent sexual transmission of HIV if applied to mucosal
surfaces prior to virus exposure.
CAPTURE OF HIV BY DENDRITIC CELLS
In vitro, infection of dendritic cells can be completely separated
from the ability of these cells to capture HIV (Blauvelt et al, 1997).
Capture of HIV by dendritic cells is mediated by the recently
identi®ed molecule called DC-SIGN (CD209) (Geijtenbeek et al,
2000b). DC-SIGN, a type II membrane protein with an external
C-type lectin domain, is expressed on the surface of immature and,
to a lesser extent, mature dendritic cells (Geijtenbeek et al, 2000c).
The natural ligands for DC-SIGN are intercellular adhesion
molecule 3 (ICAM-3) and ICAM-2, molecules that contribute to
transient dendritic cell±T cell attachment (Geijtenbeek et al, 2000c)
and to transmigration of dendritic cells across vascular endothelium,
respectively (Geijtenbeek et al, 2000a). Initially, DC-SIGN was
identi®ed through its high af®nity interaction with ICAM-3.
Surprisingly, the nucleotide sequence of this molecule was found to
be identical to a previously described HIV gp120-binding C-type
lectin isolated from a placental cDNA library (Curtis et al, 1992).
DC-SIGN and its homologs (e.g., DC-SIGN R) function as
attachment factors for HIV-1, HIV-2, and SIV (Bashirova et al,
2001; Pohlmann et al, 2001a, b). In fact, DC-SIGN af®nity for
gp120 exceeds that of CD4 (Curtis et al, 1992). Interestingly,
DC-SIGN-associated virus remains infectious for prolonged
periods of time (Geijtenbeek et al, 2000b; Smith et al, 2001) in
the absence of replication within dendritic cells. Speci®cally, HIV
captured by dendritic cells maintains infectivity for 25 d in vitro,
whereas free virus rapidly loses its infectious potential (Geijtenbeek
et al, 2000b; Smith et al, 2001).
The mechanisms that mediate prolonged survival of virions
captured by dendritic cells are unclear at present. Indeed, it is ironic
that professional antigen presenting cells such as dendritic cells, rich
in degradative compartments that are important in antigen
processing, are unable to digest HIV, and instead protect virions
in an infectious form. DC-SIGN is an ICAM-3 receptor with a
cytoplasmic domain containing well-de®ned endocytosis signals
(Engering et al, 2002; Sol-Foulon et al, 2002). Not surprisingly,
HIV bound to DC-SIGN, rather than remaining exposed on the
surface of dendritic cells, has recently been shown to traf®c through
nonlysosomal endosomal compartments (Kwon et al, 2002). This
explains why trypsin treatment of HIV-exposed dendritic cells does
not decrease the ef®ciency of dendritic-cell-mediated virus trans-
mission to T cells (Ayehunie et al, 1995). Future studies need to be
performed to elucidate the exact mechanisms by which DC-SIGN-
bound HIV resists the acidic environment of the dendritic cell
endosomal system.
THE INFECTION VERSUS CAPTURE CONTROVERSY
What are the precise biologic events that occur following sexual
exposure to HIV: infection or capture or both? The exact answer is
unknown. The genetic data mentioned earlier make it clear that
CCR5 genotype is a major determinant for HIV susceptibility
(Huang et al, 1996; Liu et al, 1996; Samson et al, 1996). Whether
CCR5 in¯uences initial infection at the level of the immature
resident Langerhans cells (primary gatekeeper model), at early
replication steps in lymphoid tissue (viral ®tness model), or both,
however, is less clear.
In support of the primary gatekeeper model, recent data from
our laboratory (A.B.) indicate that transmission of virus from
Langerhans cells to T cells is totally dependent on CCR5-mediated
infection of Langerhans cells; mannan (capable of blocking HIV
envelope interactions with C-type lectins), as well as anti-DC-
SIGN antibody, had no effect on Langerhans-cell-mediated
366 PIGUET AND BLAUVELT THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
transmission of virus to T cells (Kawamura and Blauvelt, unpub-
lished observations). Furthermore, DC-SIGN might not be
involved in sexual transmission of HIV because it is not expressed
by Langerhans cells within vaginal epithelium and epidermis
(Geijtenbeek et al, 2000b; Soilleux and Coleman, 2001). In
addition, DC-SIGN, which binds R5 and X4 viral envelopes
equally well, would not be expected to confer preferential selection
of R5 HIV that is commonly observed following initial exposure to
virus. Thus, it is likely that CCR5-mediated infection of
Langerhans cells, and not DC-SIGN-mediated capture of HIV, is
the major pathway involved in sexual transmission of HIV. Because
of this, microbicides that interfere with virus binding to CCR5
should lead to substantial protection from acquiring HIV infection
(analogous to CCR5 human ``knockouts'').
DC-SIGN-mediated capture of HIV by dendritic cells could
play a role in the early events of sexual transmission by trapping
small amounts of virus produced by Langerhans cells and amplifying
viral loads by migrating to lymph nodes and infecting T cells in
trans. Indeed, regardless of whether dendritic cells are infected with
HIV or have HIV captured in endosomal compartments, both of
these virus states render dendritic cells infectious (Fig 1).
Speci®cally, both HIV-infected dendritic cells and dendritic cells
with captured virus transmit robust infection to cocultured CD4+
T cells (Cameron et al, 1992a; Pope et al, 1994; Weissman et al,
1996; Blauvelt et al, 1997; Geijtenbeek et al, 2000b). Thus,
dendritic cell±T cell interactions, critical in the generation of
immune responses, also provide rich microenvironments for
ampli®cation of HIV replication.
In general, the level of HIV replication in dendritic cell±T cell
cocultures correlates directly with the degree of T cell activation
in vitro (Cameron et al, 1994; Tsunetsugu-Yokota et al, 1995;
Weissman et al, 1996; Blauvelt et al, 1997). In vivo, increases in viral
load that are commonly observed during opportunistic infections
(e.g., tuberculosis) may be secondary to dendritic-cell-mediated
activation and infection of memory T cells. In this setting, we can
speculate that DC-SIGN-mediated infection of T cells in trans is
the major means by which dendritic cells promote infection of T
cells, given that the absolute number of HIV-infected dendritic
cells is relatively low in chronically infected individuals (Kalter et al,
1991; Cameron et al, 1992a; von Stemm et al, 1993; McIlroy et al,
1995). Furthermore, not only does DC-SIGN promote infection of
T cells that interact with dendritic cells, this molecule also facilitates
close interaction of HIV gp120 with CD4 and HIV coreceptors on
the surface of dendritic cells, thus enhancing infection of dendritic
cells as well (Lee et al, 2001). In summary, in contrast to sexual
transmission of HIV that is mediated by CD4 and CCR5, DC-
SIGN-mediated capture of HIV, with subsequent dendritic-cell-
mediated infection of T cells during immune responses, might
contribute greatly to overall viral replication in chronic HIV
disease. If true, blocking DC-SIGN capture function, although not
interfering with the T cell stimulating potential of dendritic cells,
would be an attractive therapeutic antiviral strategy in HIV-
infected individuals.
IMMUNOTHERAPEUTIC AND PROPHYLACTIC
VACCINES USING DENDRITIC CELLS FOR HIV
DISEASE
Although HIV-speci®c immunity wanes in chronically infected
individuals, clinical studies have shown that functional immune
responses can be augmented following interruptions of highly
active antiretroviral therapy (Rosenberg et al, 2000). Because of
this, HIV researchers have long been interested in immunother-
apeutic approaches for HIV disease. Dendritic cells, representing
the best possible antigen presenting cells, are good candidate cells
for boosting immunity. In vitro, dendritic cells transduced with HIV
proteins, such as Nef or Gag (Engelmayer et al, 2001), or simply
pulsed with heat-inactivated viruses (Grovit-Ferbas et al, 2000) or
HIV RNA (Weissman et al, 2000), generate HIV-speci®c T cells.
As well, dendritic cells can process extracellular HIV antigens for
presentation by MHC class I molecules in the absence of viral
replication (Buseyne et al, 2001); this process, however, requires
adequate HIV±surface receptor interactions and fusion of viral and
cellular membranes. This ``cross-presentation'' pathway may have a
crucial role in the activation of CD8+ cytotoxic T lymphocytes
during viral infections (Sigal et al, 1999). Ultimately, the hope from
these types of studies is that dendritic cells can be isolated from
HIV-infected individuals, genetically manipulated ex vivo, re-
infused, and subsequently lead to substantial increases in HIV-
speci®c immunity and control of viral replication.
Another ®eld that bene®ts from the study of dendritic cells±HIV
interactions is gene therapy. Indeed, making use of the natural
property of HIV infection of dendritic cells, attenuated lentiviral
vectors have been shown to be ef®cient tools to genetically modify
dendritic cells. Monocyte-derived dendritic cells (Gruber et al,
2000) or CD34+ cells that can be expanded and differentiated in
dendritic cells can be ef®ciently transduced using lentiviral vectors
(Salmon et al, 2000). In contrast to retroviral vectors, lentiviral
vectors, including HIV- and SIV-derived vectors, are able to infect
slowly dividing or nondividing cells (Naldini et al, 1996). When
viral vectors are used to transduce dendritic cells, however, the viral
mechanisms of immune evasion may paralyze dendritic cell
functions. Viral mechanisms that obstruct the generation of antiviral
responses are numerous, including interference with the antigen
presentation machinery of the infected APC, inhibition of MHC
class I, MHC class II, or CD4 expression, interference with TAP
loading mechanisms, and/or the inhibition of dendritic cell
maturation (Alcami and Koszinowski, 2000; Jenne et al, 2001;
Piguet and Trono, 2001). These problems can be circumvented by
removing accessory genes that downregulate receptors and/or
antigen presentation, such as nef or vpu, from lentiviral vectors.
Using these modi®ed vectors, lentiviral transduction of dendritic
cells does not appear to affect normal dendritic cell function
(Chinnasamy et al, 2000; Dyall et al, 2001; Salmon et al, 2001). Such
vectors may be used to transduce dendritic cells in the context of
HIV infection to boost immunity, as well as in the context of
cancer immunotherapy, where dendritic cells may be transduced
with tumor antigens to break tolerance (Jenne et al, 2001).
Numerous strategies are currently being evaluated to develop an
AIDS vaccine (Nabel, 2001). In vivo targeting of resident dendritic
Figure 1. Infection of dendritic cells and capture of HIV by
dendritic cells. (1) Binding of virus to CD4 and the coreceptor CCR5.
(2) Fusion of the viral envelope with the plasma membrane and
integration in the nucleus of the infected cell. (3) Viral replication in
dendritic cells and infection of T cells with newly formed viral particles.
(4) Capture of virus by dendritic cells via the receptor DC-SIGN. Viral
particles are internalized in dendritic cells and (5) are capable of infecting
T cells in trans without de novo replication in dendritic cells. (6) The two
pathways (infection of dendritic cells and capture of HIV by dendritic
cells) converge and a high replication of virus occurs in dendritic cell±T
cell clusters.
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cells may be the best means to establish the best protective primary
immune responses. In particular, DNA-coated particles injected
into skin via gene guns and topical protein patches represent
vaccine strategies aimed at exploiting the immune-stimulating
potential of Langerhans cells within skin (Johnston and Tang, 1994;
Glenn et al, 2000). Whether these approaches will elicit better
protective immune responses against HIV compared to more
traditional vaccine delivery methods, e.g., oral and intramuscular
routes, remains to be determined.
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